Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyVolasertib for AML: clinical use and patient considerationCentrosome - a promising anti-cancer targetStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentPLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors.Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine GliomaIdentification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domainLong noncoding RNA lnc-RI is a new regulator of mitosis via targeting miRNA-210-3p to release PLK1 mRNA activity.BORA-dependent PLK1 regulation: A new weapon for cancer therapy?Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy.Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.Understanding the Polo Kinase machine.Targeted therapy of acute myeloid leukemia.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Multitarget Drugs: an Epigenetic Epiphany.Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
P2860
Q26749870-36CAC879-3B16-442C-AB22-87CB399FA146Q26801131-ED5E4A3E-6584-4F2A-AB24-F3C6C99E0A24Q28077520-BA89B434-E5AC-488A-B1D2-156EFC4EF075Q28552326-5241DBA7-BD2A-44F0-8577-80F00123E162Q28820936-DD8B7166-6552-4F33-840D-484B38A4EF9AQ30244168-B39399AF-EEC9-4166-BBDA-F43A3F95AD0DQ33873351-961B3BC0-A447-4326-A19B-2F963A9AAA8FQ35016583-AC44D8F3-251C-4029-84A7-65CD9165F612Q35801683-B0BF296C-4A2C-4CAC-9981-4C9BEBA0F934Q35832219-F1737154-76A8-4930-9B8C-3F1D49E59EC8Q35882946-92731711-28C4-4C3C-8C01-7E7218429149Q36107521-71CBDC13-1D34-474F-86AB-EF3ECCB21A16Q36190268-004005CB-DC20-493B-9693-28B31E61ECF7Q36510858-B1CE3515-F375-4F6E-9311-10009801C89BQ36516564-48BB538B-E2A9-4556-9A63-4BA7ABBD5438Q36751562-99D72136-FE16-4740-B86A-7FB916EAB4F9Q36781191-BA1E24AA-6C62-4A50-AB0C-CF4FC8B2ED72Q36886156-D0888B4B-86B8-4786-90A9-364C36053ECEQ37346526-9BC9D9E6-1D10-49AD-B62C-0483A438B4C7Q37381487-CDFDD273-C7E6-4DDC-BB1F-074D39737969Q37398885-DF64088C-988C-4146-947E-A4C2D396E605Q37447866-FB17F9FC-097A-4586-8881-A7D56F8A3A70Q37478622-6CD36140-0D52-449D-A150-667F94DDA2D7Q37720022-8DFC73C0-D53A-403B-B451-836B6FD9E1EAQ38331761-91233DE0-1604-4216-BDE7-96CEE10A0222Q38333251-8333B81A-851F-469E-9BD9-FFB535DE26C1Q38401664-97072CAA-768A-4CD3-8E2D-95281296909DQ38601723-B6D2A0EE-EF85-4BAB-A8B3-625C92534C62Q38644941-3F5512AF-AF52-4597-AFB9-72C514DAFD8DQ38651098-C599D06F-2B70-4C69-93C5-2061BBF2D41DQ38664735-D02FE63E-31D7-4FB0-BC41-A34383417366Q38739347-B264BAB1-F7CA-4333-ABD7-DE6482C4B184Q38753916-017EFAEC-DC26-4E63-A9F7-8914F22AB96EQ38788138-1D6B45F6-E659-4416-914A-53CF336B305DQ38824242-6BA5C908-17D6-40F3-9F45-15C55637186FQ38844740-70FA58AE-50D9-4D46-BD03-924FFD047481Q38872725-187A6FB2-2411-4F6C-AE1B-6D72A01FC6EDQ39372427-0AA61AC6-0773-4F13-8866-53BB1C818F5FQ41461306-C93E36F3-671C-4F13-B754-BE010885E9D5Q41582116-E3CB6A8D-EE78-4856-BEF0-C60C6D86DDDD
P2860
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@ast
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@en
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@nl
type
label
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@ast
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@en
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@nl
prefLabel
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@ast
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@en
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@nl
P2860
P921
P3181
P356
P1433
P1476
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
@en
P2093
P Schöffski
P2860
P2888
P3181
P356
10.1038/LEU.2014.222
P407
P5008
P577
2014-07-16T00:00:00Z
P5875
P6179
1009243282